Abstract：
UNASSIGNED: Various methods exist for the induction of labor (IOL), and there is limited consensus as to optimal methods. Off-label misoprostol is recommended by the World Health Organization (WHO) for IOL but preparing it into doses suitable for IOL lacks precision, with potential adverse outcomes if dosing is inaccurate. This study explores potential outcomes and costs associated with increased uptake of a low-dose (25 µg) oral misoprostol formulation (Angusta; Norgine BV, Amsterdam) approved for IOL, in France, Belgium, and the Netherlands.
UNASSIGNED: A literature review was undertaken to derive probabilities of delivery outcomes (vaginal, instrumental, and cesarean sections) for IOL methods, from published meta-analyses. Outcomes for oral misoprostol tablets (25 µg) were unavailable in the meta-analyses, so were estimated using data from two published retrospective cohort studies. A model was developed to predict the frequency of IOL outcomes and associated costs at the national level, across multiple scenarios. Scenarios were tested using a moderate, medium, and high increase in oral misoprostol tablet (25 µg) uptake. Market shares, costs, and induction rates were defined for each country using multiple data sources.
UNASSIGNED: Increased uptake of oral misoprostol tablets (25 µg) was estimated to be associated with a slightly increased rate of routine vaginal deliveries, and concurrent decreases in instrumental vaginal deliveries and cesarean sections. Since routine vaginal deliveries are less costly than other delivery outcomes, increased uptake of oral misoprostol tablets (25 µg) within the IOL market has the potential to be cost-saving. These trends were predicted using 25 µg oral misoprostol tablet outcomes informed by both retrospective studies.
UNASSIGNED: Preliminary outcomes suggest that oral misoprostol tablets at 25 µg per dose may improve outcomes in IOL and be cost-saving. Further study is required to validate these findings and assess the comparative efficacy of IOL methods, including oral misoprostol tablets (25 µg).
UNASSIGNED: A literature review was undertaken to derive probabilities of delivery outcomes (vaginal, instrumental, and cesarean sections) for IOL methods, from published meta-analyses. Outcomes for oral misoprostol tablets (25 µg) were unavailable in the meta-analyses, so were estimated using data from two published retrospective cohort studies. A model was developed to predict the frequency of IOL outcomes and associated costs at the national level, across multiple scenarios. Scenarios were tested using a moderate, medium, and high increase in oral misoprostol tablet (25 µg) uptake. Market shares, costs, and induction rates were defined for each country using multiple data sources.
UNASSIGNED: Increased uptake of oral misoprostol tablets (25 µg) was estimated to be associated with a slightly increased rate of routine vaginal deliveries, and concurrent decreases in instrumental vaginal deliveries and cesarean sections. Since routine vaginal deliveries are less costly than other delivery outcomes, increased uptake of oral misoprostol tablets (25 µg) within the IOL market has the potential to be cost-saving. These trends were predicted using 25 µg oral misoprostol tablet outcomes informed by both retrospective studies.
UNASSIGNED: Preliminary outcomes suggest that oral misoprostol tablets at 25 µg per dose may improve outcomes in IOL and be cost-saving. Further study is required to validate these findings and assess the comparative efficacy of IOL methods, including oral misoprostol tablets (25 µg).
摘要：
未经评估：存在各种引产（IOL）的方法，关于最佳方法的共识有限。世界卫生组织（WHO）建议将米索前列醇用于IOL，但将其制备成适合IOL的剂量缺乏精确性，如果给药不准确，则有潜在的不良后果。本研究探讨了与低剂量（25µg）口服米索前列醇制剂（Angusta；NorgineBV，阿姆斯特丹）批准用于IOL，在法国,比利时,和荷兰。
UNASSIGNED：进行了文献综述，以得出分娩结果的概率（阴道，器乐,和剖宫产)用于IOL方法，来自发表的荟萃分析。meta分析中没有口服米索前列醇片剂（25µg）的结果，使用两项已发表的回顾性队列研究的数据进行估计。开发了一个模型来预测国家层面的IOL结果和相关成本的频率，跨多个场景。使用适度的测试方案，中等,和高增加口服米索前列醇片剂（25µg）摄取。市场份额,成本,并使用多个数据源定义每个国家的诱导率。
UNASSIGNED：估计口服米索前列醇片（25µg）的摄取增加与常规阴道分娩率略有增加有关，工具性阴道分娩和剖宫产的同时减少。由于常规阴道分娩的成本低于其他分娩结果，IOL市场中口服米索前列醇片剂(25µg)的摄入量增加有可能节省成本.这些趋势是使用25µg口服米索前列醇片剂结果预测的，这两个回顾性研究都提供了信息。
UNASSIGNED：初步结果表明，口服米索前列醇片每剂25µg可能会改善IOL的结果并节省成本。需要进一步的研究来验证这些发现并评估IOL方法的比较疗效。包括口服米索前列醇片剂（25µg）。
UNASSIGNED：进行了文献综述，以得出分娩结果的概率（阴道，器乐,和剖宫产)用于IOL方法，来自发表的荟萃分析。meta分析中没有口服米索前列醇片剂（25µg）的结果，使用两项已发表的回顾性队列研究的数据进行估计。开发了一个模型来预测国家层面的IOL结果和相关成本的频率，跨多个场景。使用适度的测试方案，中等,和高增加口服米索前列醇片剂（25µg）摄取。市场份额,成本,并使用多个数据源定义每个国家的诱导率。
UNASSIGNED：估计口服米索前列醇片（25µg）的摄取增加与常规阴道分娩率略有增加有关，工具性阴道分娩和剖宫产的同时减少。由于常规阴道分娩的成本低于其他分娩结果，IOL市场中口服米索前列醇片剂(25µg)的摄入量增加有可能节省成本.这些趋势是使用25µg口服米索前列醇片剂结果预测的，这两个回顾性研究都提供了信息。
UNASSIGNED：初步结果表明，口服米索前列醇片每剂25µg可能会改善IOL的结果并节省成本。需要进一步的研究来验证这些发现并评估IOL方法的比较疗效。包括口服米索前列醇片剂（25µg）。
